22 May 2013
Keywords: Salix Pharma, Xifaxan, Irritable bowel syndrome, IBS, CRL, USA, FDA
Article | 09 March 2011
As was largely anticipated, the US Food and Drug Administration issued a Complete Response Letter (CRL) late Monday for Salix ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 March 2011
21 May 2013
© 2013 thepharmaletter.com